EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Unveiling trends: insights into medicines reimbursement recommendations and health technology management in Ireland (2018–2023)

David Aluga iD, Claire Gorry, Michael Barry, Paula Byrne, Paddy Gillespie, Susan M Smith

International Journal of Technology Assessment in Health Care · 2026 · 42 (1)

DOI: 10.1017/s0266462326103717 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Technology Assessment in Health Care, online erschienen am 06.04.2026. Verfasst von David Aluga und 5 weiteren Autor:innen. Beteiligte Einrichtung: Discipline of Public Health and Primary Care, Institute of Population Health, School of Medicine, https://ror.org/02tyrky19Trinity College Dublin, Ir…. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical, Reimbursement Mechanisms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Health technology management (HTM) involves systems designed to ensure the safe, effective, and cost-effective use of health technologies following reimbursement. This study examines the recommendations of Ireland’s Health Service Executive-Drugs Group (HSE-DG), exploring the characteristics and patterns of positive or conditional positive recommendations and HTM-related requirements.

Methods

We reviewed the minutes of HSE-DG meetings between January 2018 and December 2023. Data on medicines reviewed during this period were extracted into Microsoft Excel and analyzed narratively.

Results

Over the study period, the HSE-DG reviewed 192 medicines (including new medicines and new indications for existing medicines), of which 157 received positive (115) or conditional positive recommendations (42). Of these, thirty-three were subject to HTM conditions, typically involving a managed access protocol or a specific reimbursement application process. Due to inconsistent reporting of key information, quantitative analysis was not feasible. However, common characteristics among HTM-linked recommendations emerged. These included submissions for reimbursement targeting a subset of the licensed population (45.5 percent vs. 5.6 percent in non-HTM cases), designation as orphan medicines (39.4 percent vs. 29.8 percent), and having both first-in-class and new chemical entity designations (75.8 percent vs. 47.6 percent).

Conclusions

Findings indicate an increasing trend toward positive/conditional positive reimbursement recommendations with HTM in the Irish setting, with an average of 21 percent of positive/conditional positive recommendations over the study period contingent on HTM. More granular and consistent reporting of key indicators would enable the determination of characteristics associated with reimbursement recommendations with HTM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Technology Assessment, BiomedicalReimbursement MechanismsIrelandHumansCost-Benefit Analysis

Stichwörter der Autor:innen

health technology assessmenthealth technology managementmanaged access protocolsorphan drugsreimbursement

Autor:innen und Institutionen

  • Discipline of Public Health and Primary Care, Institute of Population Health, School of Medicine, https://ror.org/02tyrky19Trinity College Dublin, Ireland.
  • Health Service Executive-Medicines Management Programme, Trinity Centre for Health Sciences, https://ror.org/04c6bry31St. James's Hospital, Dublin, Ireland.
  • Department of Pharmacology and Therapeutics, School of Medicine, https://ror.org/02tyrky19Trinity College Dublin, Dublin, Ireland.
  • Centre for Health Research Methodology, College of Medicine, Nursing and Health Sciences, https://ror.org/03bea9k73University of Galway, Ireland.
  • Health Economics and Policy Analysis Centre, J.E. Cairnes School of Business & Economics, https://ror.org/03bea9k73University of Galway, Ireland.

ORCID-Profile: David Aluga

Zitieren

APA

Aluga, D., Gorry, C., Barry, M., Byrne, P., Gillespie, P., & Smith, S. M. (2026). Unveiling trends: insights into medicines reimbursement recommendations and health technology management in Ireland (2018–2023). International Journal of Technology Assessment in Health Care, 42(1). https://doi.org/10.1017/s0266462326103717

Vancouver

Aluga D, Gorry C, Barry M, Byrne P, Gillespie P, Smith SM. Unveiling trends: insights into medicines reimbursement recommendations and health technology management in Ireland (2018–2023). International Journal of Technology Assessment in Health Care. 2026;42(1). doi:10.1017/s0266462326103717

BibTeX
@article{Aluga2026,
  author = {Aluga, David and Gorry, Claire and Barry, Michael and Byrne, Paula and Gillespie, Paddy and Smith, Susan M},
  title = {Unveiling trends: insights into medicines reimbursement recommendations and health technology management in Ireland (2018–2023)},
  journal = {International Journal of Technology Assessment in Health Care},
  year = {2026},
  volume = {42},
  number = {1},
  doi = {10.1017/s0266462326103717}
}
Kostenlos starten →